Participation of cyclooxygenase pathway in the vasoconstriction induced by 5-HT in the in situ autoperfused kidney of long-term diabetic rats

European Journal of Pharmacology
B RestrepoA Morán

Abstract

We attempted to characterize the 5-hydroxytryptamine (5-HT) receptor type/subtype and mediator mechanisms involved in the contractile effects of 5-HT in the in situ autoperfused kidney of long-term diabetic rats. Diabetes was induced in male Wistar rats by a single subcutaneous injection of alloxan. Intra-arterial (i.a.) bolus injection of 5-HT (0.00000125 to 0.1μg/kg) increased renal perfusion pressure in a dose dependent way but did not affect the systemic blood pressure in long-term diabetic rats. The selective 5-HT2 receptor agonist, α-methyl-5-HT, caused a local vasoconstrictor effect in the in situ autoperfused rat kidney similar to 5-HT. However, BW723C86, a selective 5-HT2B receptor agonist, m-CPP (1-(3-chlorophenyl)piperazine), a selective 5-HT2B/2C receptor agonist, the 5-HT1 receptor agonist, 5-carboxamidotryptamine (5-CT), and the selective 5-HT3 receptor agonist, 1-phenylbiguanide did not modify the renal perfusion pressure. In long-term diabetic rats, vasoconstriction elicited by 5-HT and α-methyl-5-HT was significantly decreased by ritanserin (a 5-HT2 receptor antagonist), spiperone (a 5-HT2A receptor antagonist), and the cyclooxygenase (COX) inhibitors, indomethacin (non-selective COX inhibitor), FR 122047 or ni...Continue Reading

References

Jan 1, 1990·Journal of Cardiovascular Pharmacology·M H ZinkR H Alper
May 1, 1987·Journal of Cardiovascular Pharmacology·D K AgrawalJ H McNeill
Oct 1, 1985·Circulation·P M Vanhoutte, D S Houston
Jan 1, 1972·Naunyn-Schmiedeberg's Archives of Pharmacology·G Haeusler, L Finch
Feb 1, 1993·Kidney International·K EndlichM Steinhausen
Oct 10, 1998·Kidney International·M KashoM Shichiri
Jan 8, 1999·Naunyn-Schmiedeberg's Archives of Pharmacology·T Van BurenD J De Wildt
Apr 4, 2001·The Journal of Clinical Investigation·Radko KomersSharon Anderson
Feb 9, 2002·British Journal of Pharmacology·Takehiro Ochi, Toshio Goto
Jan 16, 2004·The Journal of Pharmacology and Experimental Therapeutics·Stephanie W Watts, Janice M Thompson
May 11, 2005·Kidney International·Radko KomersSharon Anderson
Nov 9, 2007·Annual Review of Physiology·Chuan-Ming Hao, Matthew D Breyer
Dec 17, 2008·Trends in Pharmacological Sciences·Andrew G Ramage, Carlos M Villalón

Citations

Apr 10, 2015·Clinical and Experimental Pharmacology & Physiology·José-Ángel García-PedrazaA Morán
May 25, 2015·Vascular Pharmacology·José-Ángel García-PedrazaA Morán
Sep 24, 2016·Scientific Reports·José-Ángel García-PedrazaA Morán
Jan 31, 2019·Hypertension Research : Official Journal of the Japanese Society of Hypertension·José Ángel García-PedrazaA Morán
Nov 11, 2020·Scientific Reports·José Ángel García-PedrazaCarlos M Villalón

Related Concepts

Alloxan
Arteries
Diabetes
Indomethacin
Kidney
Prazosin
Propranolol
Rats, Wistar
Serotonin
Spiperone

Related Feeds

Bioinformatics in Biomedicine

Bioinformatics in biomedicine incorporates computer science, biology, chemistry, medicine, mathematics and statistics. Discover the latest research on bioinformatics in biomedicine here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.